Pfizer Stock Price, News & Analysis

Pfizer (PFE) has provided its full-year 2025 guidance, projecting revenue between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company expects operational revenue growth of flat to 5% compared to 2024, with adjusted diluted EPS operational growth of 10% to 18%.

The company has achieved its goal of $4.0 billion in net cost savings through 2024 and anticipates an additional $500 million in savings in 2025. The guidance considers a $1 billion unfavorable impact from the Inflation Reduction Act Part D Redesign changes. Pfizer's 2025 adjusted expenses are projected at $13.3 to $14.3 billion for SI&A and $10.7 to $11.7 billion for R&D.

Pfizer (NYSE: PFE) has announced an increase in its quarterly cash dividend to $0.43 per share for the first quarter of 2025. The dividend will be paid on March 7, 2025, to shareholders of record as of January 24, 2025. This marks Pfizer's 345th consecutive quarterly dividend payment, demonstrating the company's commitment to shareholder returns. Chairman and CEO Dr. Albert Bourla emphasized that this dividend increase reflects Pfizer's strong financial performance and disciplined execution.

Pfizer (PFE) and Alliance Foundation Trials announced significant results from the Phase 3 PATINA trial for IBRANCE® in treating HR+, HER2+ metastatic breast cancer. The trial demonstrated that adding IBRANCE to standard first-line maintenance therapy significantly improved progression-free survival (PFS). Patients treated with IBRANCE combination therapy achieved a median PFS of 44.3 months compared to 29.1 months for those on standard therapy alone, representing a 15-month improvement.

The safety profile aligned with previous known data, with common adverse events including neutropenia, leukopenia, fatigue, stomatitis, and diarrhea. IBRANCE, approved since 2015, has been prescribed to over 773,000 patients and is approved in more than 108 countries. Pfizer plans to present these findings to regulatory authorities.

Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for December 17, 2024, at 8:30 a.m. EST. The primary purpose is to present the company's full-year 2025 financial guidance.

Investors and the public can access the webcast through www.pfizer.com/investors. Participants can join via webcast or by phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (international), with passcode '85344'.

The webcast replay and transcript will be available on Pfizer's investor website within 24 hours after the live call and will remain accessible for at least 90 days.

Scorpion Therapeutics announced updates for its PI3Kα inhibitor STX-478, including a new collaboration with Pfizer to evaluate a triplet combination therapy for metastatic breast cancer. The collaboration will study STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer, with trial initiation planned for 2H25.

Updated Phase 1/2 study results presented at SABCS 2024 showed STX-478 achieved a 23% overall response rate in HR+/HER2- breast cancer and 44% ORR in gynecological tumors. The drug demonstrated favorable safety with minimal dose modifications and no patient discontinuations due to adverse events. The study also revealed a positive dose-response relationship in monotherapy treatment.

Pfizer will present over 100 research abstracts at the American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium (SABCS) in December. The presentations include data from approved medicines and pipeline candidates for blood and breast cancers, and rare blood disorders.

Key highlights include updated analyses from the ECHELON-3 trial for ADCETRIS in DLBCL, new data for ELREXFIO in multiple myeloma, and nine real-world analyses confirming IBRANCE as a first-line treatment for HR+/HER2- metastatic breast cancer. The company will also present new Phase 1 data for innovative therapies including atirmociclib, vepdegestrant, and PF-07248144.

The presentations span multiple therapeutic areas including hemophilia, with results from the Phase 3 AFFINE gene therapy trial, and sickle cell disease research.

Zai Lab (NASDAQ: ZLAB) and Pfizer announced a strategic collaboration for XACDURO® (sulbactam-durlobactam) in mainland China through November 2028. Pfizer will exclusively handle commercialization activities for XACDURO®, leveraging its anti-infective infrastructure. XACDURO® is the only antimicrobial specifically developed for treating carbapenem-resistant Acinetobacter baumannii (CRAB) in hospital-acquired and ventilator-associated bacterial pneumonia. In China, where Acinetobacter baumannii resistance to carbapenem antibiotics has reached approximately 74%, this collaboration aims to accelerate patient access to this critical therapy.

Pfizer (NYSE: PFE) has appointed Dr. Chris Boshoff as Chief Scientific Officer and President, Research & Development, effective January 1, 2025. Dr. Boshoff, previously Chief Oncology Officer, will oversee all R&D functions across therapeutic areas. During his 11-year tenure at Pfizer, he has delivered 24 approved innovative medicines and biosimilars across 30+ indications.

The company also announced that Roger Dansey will serve as Interim Chief Oncology Officer, while Johanna Bendell will join from Roche as Oncology Chief Development Officer. The Oncology R&D organization will maintain its integrated structure, reporting to Dr. Boshoff.

Pfizer (NYSE: PFE) has received European Commission approval for HYMPAVZI™ (marstacimab), a groundbreaking treatment for severe hemophilia A or B without inhibitors in patients 12 years and older. This marks the first once-weekly subcutaneous treatment approved for severe hemophilia B and the first pre-filled pen/syringe administration option for both types in the EU. The approval is based on Phase 3 study results showing a 35% reduction in annualized bleeding rate compared to routine prophylaxis. HYMPAVZI demonstrated both non-inferiority and superiority to standard treatments, with common side effects including injection site reactions, headache, pruritus, and hypertension.